These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 21796848)
1. It is anticipated that as is usually the case, financial motivation will move TZ from its current status “potential anti-MDR/XDR agent,” to one that will cure MDR and XDR TB. Foreword. Amaral L Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):76. PubMed ID: 21796848 [No Abstract] [Full Text] [Related]
2. Effective therapy with the neuroleptic thioridazine as an adjunct to second line of defence drugs, and the potential that thioridazine offers for new patents that cover a variety of "new uses". Amaral L; Viveiros M; Molnar J; Kristiansen JE Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):84-7. PubMed ID: 21548876 [TBL] [Abstract][Full Text] [Related]
3. XDR-TB, what is it; how is it treated; and why is therapeutic failure so high? Gillespie SH; Singh K Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):77-83. PubMed ID: 21595627 [TBL] [Abstract][Full Text] [Related]
4. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. Amaral L; Martins M; Viveiros M; Molnar J; Kristiansen JE Curr Drug Targets; 2008 Sep; 9(9):816-9. PubMed ID: 18781927 [TBL] [Abstract][Full Text] [Related]
5. Global clinical trials for the treatment of TB with thioridazine. Boeree MJ Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):99-103. PubMed ID: 21548879 [TBL] [Abstract][Full Text] [Related]
6. Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent "as new use". Amaral L; Molnar J Recent Pat Antiinfect Drug Discov; 2010 Jun; 5(2):109-14. PubMed ID: 20156179 [TBL] [Abstract][Full Text] [Related]
7. Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)--a novel, patentable approach to limit the emergence of XDR-TB. Martins M Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):110-7. PubMed ID: 21517742 [TBL] [Abstract][Full Text] [Related]
8. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance. Lohrasbi V; Talebi M; Bialvaei AZ; Fattorini L; Drancourt M; Heidary M; Darban-Sarokhalil D Tuberculosis (Edinb); 2018 Mar; 109():17-27. PubMed ID: 29559117 [TBL] [Abstract][Full Text] [Related]
9. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Amaral L; Viveiros M Int J Antimicrob Agents; 2012 May; 39(5):376-80. PubMed ID: 22445204 [TBL] [Abstract][Full Text] [Related]
10. New patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: a gene regulation perspective. Dutta NK; Mazumdar K; Dastidar SG; Karakousis PC; Amaral L Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):128-38. PubMed ID: 21517741 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms by which thioridazine in combination with antibiotics cures extensively drug-resistant infections of pulmonary tuberculosis. Amaral L; Molnar J In Vivo; 2014; 28(2):267-71. PubMed ID: 24632985 [TBL] [Abstract][Full Text] [Related]
12. The mechanism by which the phenothiazine thioridazine contributes to cure problematic drug-resistant forms of pulmonary tuberculosis: recent patents for "new use". Amaral L; Martins A; Spengler G; Hunyadi A; Molnar J Recent Pat Antiinfect Drug Discov; 2013 Dec; 8(3):206-12. PubMed ID: 24320229 [TBL] [Abstract][Full Text] [Related]
13. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Amaral L; Boeree MJ; Gillespie SH; Udwadia ZF; van Soolingen D Int J Antimicrob Agents; 2010 Jun; 35(6):524-6. PubMed ID: 20188526 [TBL] [Abstract][Full Text] [Related]
14. Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study. Guglielmetti L; Veziris N; Aubry A; Brossier F; Bernard C; Sougakoff W; Jarlier V; Robert J Int J Tuberc Lung Dis; 2018 Jan; 22(1):54-59. PubMed ID: 29297426 [TBL] [Abstract][Full Text] [Related]
15. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154 [TBL] [Abstract][Full Text] [Related]
16. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis. Blöndal K; Viiklepp P; Guðmundsson LJ; Altraja A Int J Tuberc Lung Dis; 2012 Sep; 16(9):1228-33. PubMed ID: 22748131 [TBL] [Abstract][Full Text] [Related]
17. Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results. Migliori GB; Lange C; Girardi E; Centis R; Besozzi G; Kliiman K; Ortmann J; Matteelli A; Spanevello A; Cirillo DM; Clin Infect Dis; 2008 Mar; 46(6):958-9. PubMed ID: 18288911 [No Abstract] [Full Text] [Related]
18. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. Park SK; Kim JH; Kang H; Cho JS; Smego RA Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB. Udwadia ZF; Sen T; Pinto LM Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):88-91. PubMed ID: 21631417 [TBL] [Abstract][Full Text] [Related]